Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Jacqueline Vuky; Richard Yu; Lawrence Schwartz; Robert J. Motzer

doi:10.1023/A:1016270206374

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Jacqueline Vuky
, Richard Yu
, Lawrence Schwartz
, Robert J. Motzer

Research output: Contribution to journal › Article › peer-review

77 Scopus citations

Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As₂O₃). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

Original language	English (US)
Pages (from-to)	327-330
Number of pages	4
Journal	Investigational New Drugs
Volume	20
Issue number	3
DOIs	https://doi.org/10.1023/A:1016270206374
State	Published - 2002
Externally published	Yes

Funding

Supported in part by NIH Grants K24 CA-82431, CA-0582, 5T32-CA-09207-23 (Cancer Chemotherapy Training Program), and the Brian Piccolo Cancer Research Fund.

Funders	Funder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health	CA-0582, K24 CA-82431, 5T32-CA-09207-23
National Institute of Health-National Cancer Institute	T32CA009207
Brian Piccolo Cancer Research Fund

Keywords

Arsenic trioxide
Metastatic renal cell carcinoma
Phase II trial

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/A:1016270206374

Cite this

@article{e0de0a98b37646289e55b31f2aa3a42c,

title = "Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma",

abstract = "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70\%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36\%), anemia (21\%), renal insufficiency (14\%), rash (7\%), and diarrhea (7\%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.",

keywords = "Arsenic trioxide, Metastatic renal cell carcinoma, Phase II trial",

author = "Jacqueline Vuky and Richard Yu and Lawrence Schwartz and Motzer, \{Robert J.\}",

note = "Funding Information: Supported in part by NIH Grants K24 CA-82431, CA-0582, 5T32-CA-09207-23 (Cancer Chemotherapy Training Program), and the Brian Piccolo Cancer Research Fund.",

year = "2002",

doi = "10.1023/A:1016270206374",

language = "English (US)",

volume = "20",

pages = "327--330",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

AU - Vuky, Jacqueline

AU - Yu, Richard

AU - Schwartz, Lawrence

AU - Motzer, Robert J.

N1 - Funding Information: Supported in part by NIH Grants K24 CA-82431, CA-0582, 5T32-CA-09207-23 (Cancer Chemotherapy Training Program), and the Brian Piccolo Cancer Research Fund.

PY - 2002

Y1 - 2002

N2 - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

AB - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

KW - Arsenic trioxide

KW - Metastatic renal cell carcinoma

KW - Phase II trial

UR - https://www.scopus.com/pages/publications/0036021225

UR - https://www.scopus.com/pages/publications/0036021225#tab=citedBy

U2 - 10.1023/A:1016270206374

DO - 10.1023/A:1016270206374

M3 - Article

C2 - 12201495

AN - SCOPUS:0036021225

SN - 0167-6997

VL - 20

SP - 327

EP - 330

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this